Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy

A sec­ond out­comes-based agree­ment with an uniden­ti­fied pay­er is now in the books for blue­bird bio’s new $3.1 mil­lion sick­le cell gene ther­a­py, the com­pa­ny said Thurs­day in an SEC fil­ing.

The an­nounce­ment brings the cu­mu­la­tive to­tal of cov­ered lives for the ther­a­py known as Lyf­ge­nia to ap­prox­i­mate­ly 200 mil­lion peo­ple, sug­gest­ing that the biotech has locked up broad cov­er­age from ma­jor in­sur­ers af­ter fac­ing doubts about its com­mer­cial strat­e­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.